His research interest is the study of the molecular and cellular mechanisms acting in the natural history of Chronic Lymphocytic Leukemia (CLL), including Monoclonal B-cell Lymphocytosis (MBL) with the overall aim of translating the knowledge into the definition of more reliable prognostic markers and more targeted therapies. On these topics he has published over 260 manuscripts in peer-reviewed journals. He is President of the European Research Initiative on CLL (ERIC), collaborating to the guidelines for the detection of Minimal Residual Disease (MRD), for the analysis of the mutational status of the immunoglobulin (IGHV) genes and of the TP53 gene aberrations.



HONORS AND MEMBERSHIPS IN PROFESSIONAL SOCIETIES
1997 – present American Society of Hematology, member
1997 – present American Association of Immunologists, member
2002 – present European Hematology Association, member
2002 – present Società Italiana di Immunologia, Immunologia Clinica e Allergologia, member
2006 – present Henry Kunkel Society, member
2006 – 2009 co-chairman of the Basic and Translational Research Committee of the European Research Initiative on CLL (ERIC)
2007 – today Società Italiana di Ematologia Sperimentale (SIES), member
2007 – 2009 Member of the Scientific Program Committee – Advisory Board (SPC-AB) of the European Hematology Association (EHA)
2007 – 2008 Co-organizer, II and III edition, “Young CLL Investigators Meeting” (London 2007; Cologne 2008)
2007 – today Member, Organizing and Scientific Committee of the Annual “Educational Workshop of Immunoglobulin Genes analysis in Chronic Lymphocytic Leukemia” (Uppsala, 2007; Paris, 2008; Thessaloniki 2009),